SCHEMBL4883196

SCHEMBL4883196

O=C(N/N=C(\C=N\O)c1ccccc1)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.49
NPC1 O15118 5/20 0.49
LMNA P02545 1/20 0.45
CRHBP P24387 1/20 0.45
CRHR2 Q13324 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 3/20 0.44
P2RX1 P51575 1/20 0.43
KDM4E B2RXH2 2/20 0.43
MAPT P10636 2/20 0.43
GLA P06280 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MTOR P42345 2/20 0.43
CYP1A1 P04798 1/20 0.43
MAOB P27338 1/20 0.43
CYP1B1 Q16678 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
PTGS1 P23219 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4883201 1.00 RAB9A (0.49) RAB9ANPC1LMNACRHBPCRHR2
SCHEMBL4885748 0.90 P2RX1 (0.48) RAB9ANPC1LMNAMEN1KMT2A
SCHEMBL5715915 0.89 NPC1 (0.53) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL5715919 0.89 NPC1 (0.53) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL4885958 0.88 LMNA (0.54) LMNAMEN1KMT2AALDH1A1P2RX1
SCHEMBL4885965 0.88 LMNA (0.54) LMNAMEN1KMT2AALDH1A1P2RX1
SCHEMBL4883238 0.87 ALDH1A1 (0.54) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL4883234 0.87 ALDH1A1 (0.54) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL4884919 0.86 ESRRG (0.56) RAB9ANPC1LMNAMEN1KMT2A
SCHEMBL4884917 0.86 ESRRG (0.56) RAB9ANPC1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227787-A1 Use of New Lipoxygenase Inhibitors BIOLIPOX AB (SE) 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227787-A1 Use of New Lipoxygenase Inhibitors ALOX15, ALOX15B, ALOX12 RAB9A 3811/4885NPC1 2644/4885LMNA 2096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.